<DOC>
	<DOCNO>NCT02919345</DOCNO>
	<brief_summary>Background Endothelial dysfunction one early event atherosclerotic plaque development . It characterize increase ratio substance vasoconstrictive , pro-thrombotic , proliferative property substance vasolidatory , antithrombogenic antimitogenic property . Endothelial dysfunction also associate high-risk patient coronary artery disease . Hyperglycemia , obesity , hypertension fat mass also impair endothelium increase expression cytokine , inflammatory marker vascular marker . Hypothesis Administration dapagliflozin addition metformin background clinical subclinical cardiovascular atherosclerotic disease improve endothelial function compare use glibenclamide addition metformin . Objectives Evaluate effect dapagliflozin v glibenclamide metformin background endothelial function patient clinical subclinical cardiovascular atherosclerotic disease poorly control diabetes . Enpoints Prymary Change flow mediate dilation ( FMD ) relate endpoint ( FMD post reperfusion lesion ) randomization visit 12 week treatment . Secondary Change plasma nitric oxide , isoprostane , ICAM-1 , VCAM-1 , ET-1 , leptin , adiponectin , C-reactive protein , TNF- α , interleukin-6 , interleukin-2 , weight body composition ( % fat mass % free fat mass ) randomization visit 12 week treatment . 3 Design Randomized , parallel-group , comparative , prospective clinical study . The study divide two phase : Run-in Randomization . In former phase , must maximum period 16 week , patient visit outpatient adjust metformin blood pressure medication . After run-in phase , patient fulfill inclusion criterion perform ambulatory blood pressure monitoring ( ABPM ) order ass BP ; body composition assess dual x-ray absorptiometry ( DXA ) ; endothelial function assess flow mediate dilation vascular cytokine . Patients randomize dapagliflozin glibenclamide metformin background . After 12 week , ABPM , DXA endothelial function assess .</brief_summary>
	<brief_title>Assessment Dapagliflozin Effect Diabetic Endothelial Dysfunction Brachial Artery</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>( ) chronic coronary artery disease show angiogram subclinical artery disease diagnose presence carotid atherosclerotic plaque carotid IntimaMedia Thickness ( cIMT ) ≥ 1mm ; ( ii ) T2DM use two oral hypoglycemic agent ; ( iii ) inadequate glycemic control ( HbA1c ≥ 7 % ) ; ( ) HbA1c &gt; 9 % ; ( ii ) contraindication metformin use ( Cr Clearance &lt; 60 ml/min , Cr &gt; 1.5 mg/dL men &gt; 1.4 mg/dl woman , liver failure AST ALT &gt; 3x upper normal limit condition might increase risk lactic acidosis ) ; ( vi ) time randomization , patient metformin XR 1500 mg/day monotherapy least 12 week ; ( vii ) patient spend 16 week adjust metformin randomization ; ( viii ) BP ≥ 140 x 90 16 week antihypertensive medication adjustment ; ( iii ) hospitalization unstable angina acute myocardial infarction within 2 month prior enrolment ; ( iv ) acute stroke transient ischemic attack ( TIA ) within two month prior enrolment ; ( v ) less two month post coronary artery revascularization ; ( ix ) patient FMD &lt; 2 % time randomization ; ( x ) triglycerides &gt; 500 mg/dL ; ( xi ) know allergy study drug ; ( xii ) patient severe coronary artery disease heart failure ; ( xiii ) systemic vasculitis ; ( xiv ) condition lead systemic inflammation ; ( xv ) patient use rosiglitazone ; ( xvi ) polyuria , polydipsia , weight loss , others clinical sign volume depletion ; ( xvii ) refuse participate sign Statement Informed Consent ; ( xviii ) pregnancy woman reproductive age ; ( xix ) breastfeed woman ; ( xx ) history gastrointestinal disorder may interfere absorption study medication ; ( xxi ) patient participate clinical study whose participation end less six month ago .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Dapagliflozin</keyword>
	<keyword>Glibenclamide</keyword>
	<keyword>Endothelial Function</keyword>
	<keyword>Vascular Endothelial Cells</keyword>
	<keyword>Flow Mediated Dilation</keyword>
</DOC>